Philip Morris (PM) Q2 2026: A Great Quarter GAAP Hides — Smoke-Free Winner at a Full Price? HOLD

Philip Morris International (PM) Q2 2026 — Philip Morris International (PM) reported Q2 2026 results that look contradictory at the headline but are strong underneath. Reported GAAP diluted EPS FELL 7.7% YoY to $1.80 — but that entire drop is a $511M non-cash impairment of its deconsolidated Canadian affiliate (RBH), worth 33c/share. On the measure management runs the business, ADJUSTED diluted EPS jumped 15.2% to $2.20 (+13.6% ex-currency), beating the ~$2.04 estimate. Net revenues topped $11.2B for the first time ever (+10.4% reported, +7.6% organic), operating income rose 22%, and the smoke-free business (IQOS + ZYN + VEEV) grew ~12% to ~42% of revenue, now in 109 markets. Combustibles still grew ~10% on 10% pricing — remarkable power for a declining-volume product. PM RAISED its FY2026 adjusted-EPS outlook to $8.26–$8.41 (+9.5% to +11.5%), though only for currency (favorable FX trimmed from $0.20 to $0.15). The catch: the stock (~$188) sits just below its all-time high near $195, trades at ~23x adjusted earnings with only a ~3% yield (a premium-staples multiple), carries ~$44B of net debt after Swedish Match (buybacks suspended to deleverage), and earns 100% of revenue outside the U.S. (constant FX risk). On an owner-earnings / FCF DCF net of ~$44B net debt (7/8/9% discount, base ~$13.5B FCF), our probability-weighted fair value is ~$170 — a bit BELOW the ~$188 price. Our call: HOLD, 3/5 — a great business at a full price, modestly more cautious than the Street's Buy / ~$200 average target (which itself is only ~6% above the price). Philip Morris International is no longer just a cigarette company — it's a smoke-free champion. It sells Marlboro and other cigarettes everywhere outside the U.S. (a mature, pricing-powered cash cow), but the real story is the pivot to smoke-free: it owns IQOS (the leading heat-not-burn device, ~three-quarters of its global category), ZYN (the US nicotine-pouch phenomenon), and VEEV (e-vapor). Smoke-free products are now sold in 109 markets, used by 43M+ people, and account for ~42% of revenue. Q2 2026 looked contradictory at the headline: reported GAAP diluted EPS FELL 7.7% to $1.80 — but that entire decline is a $511M non-cash impairment of the deconsolidated Canadian affiliate (RBH), worth 33c/share, and says nothing about how IQOS or ZYN are selling. On the adjusted basis management runs the business by, EPS jumped 15.2% to $2.20 (+13.6% ex-currency), beating the ~$2.04 estimate. Net revenues topped $11.2B for the first time (+10.4% reported, +7.6% organic), operating income rose 22%, gross margin expanded, and the smoke-free business grew ~12%. The bull case is genuine: IQOS volumes +8% holding ~75% category share, ZYN with fresh first-ever FDA MRTP authorization for 20 variants (~2.9B pouches), and combustibles taking +10% price — proving Marlboro funds the whole transition. Management RAISED FY2026 adjusted-EPS guidance to $8.26–$8.41 (currency only). So why only a HOLD? Because the quality is not a secret and the price already reflects it. PM trades at ~23x adjusted earnings and ~18x cash flow with only a ~3% yield — a premium-staples multiple, closer to Coca-Cola (~26x) than to tobacco peers Altria (~15x) or BTI (~13x), which yield 5%+. It sits just below its all-time high, carries ~$44B of net debt after the Swedish Match deal (buybacks suspended to deleverage toward ~2x by year-end), and earns 100% of revenue outside the U.S., so a strong dollar is a constant headwind — exactly why guidance moved this quarter. Valuing a stable, pricing-powered compounder on owner earnings — normalized FCF of ~$13.5B/yr, discounted at 7/8/9% and net of ~$44B net debt — our two-scenario DCF spans ~$140–$210 (base, smoke-free offsets combustible decline, +5% FCF growth) and ~$175–$280 (bull, IQOS+ZYN compound, +7%), with a genuine ~$120 downside if combustibles fade faster or the dollar stays strong. Probability-weighted (50% base $170 / 25% bull $215 / 25% bear $120), fair value is ~$170 — a touch below the ~$188 price. That's no margin of safety for new money. Notably, even the Street's Buy rating carries an average target of only ~$200 — just ~6% above the price — so even the bulls see limited upside. Our verdict: HOLD, 3/5 — a world-class, smoke-free compounder and a genuinely strong quarter, but fully priced near its all-time high. A company to admire, and a price to wait on. Not financial advice. THE CALL: HOLD (3/5, A WORLD-CLASS, PRICING-POWERED SMOKE-FREE COMPOUNDER (IQOS + ZYN) THAT JUST POSTED A STRONG QUARTER THE GAAP HEADLINE HIDES — BUT TRADES AT A PREMIUM-STAPLES MULTIPLE NEAR ITS ALL-TIME HIGH, WITH ~$44B NET DEBT AND 100% FX EXPOSURE, LEAVING NO MARGIN OF SAFETY AT ~$188 VS OUR ~$170 FAIR VALUE) — base-case value ~$170 vs ~$188 today. What to watch: Watch the smoke-free growth rate (IQOS volumes + ZYN) and the debt trajectory above all else — those two numbers decide whether the premium is earned. We'd turn more constructive on a pullback toward ~$160 or below (where the dividend yield rises toward 4% and a real margin of safety opens up), or on continued double-digit smoke-free growth PLUS visible debt paydown toward the ~2x leverage target (which would resume buybacks and justify a higher value — the path toward the bull case). The risks to respect: an accelerating decline in cigarette volumes, a sustained strong dollar squeezing reported guidance (PM earns 100% ex-US), or a regulatory shock on IQOS or ZYN (excise-tax hikes like Japan, flavor bans like Poland) — any of which pulls value toward the ~$120 bear case. At ~$188 vs our ~$170 prob-weighted fair value, there's no margin of safety, which is why we wait rather than chase. Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.